Shares of Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) ended Monday session in red amid volatile trading. The shares closed down -0.007 points or -0.70% at $0.983 with 1.40 million shares getting traded. Post opening the session at $0.99, the shares hit an intraday low of $0.95 and an intraday high of $1.02 and the price vacillated in this range throughout the day. The company has a market cap of $154.19 million and the numbers of outstanding shares have been calculated to be 155.75 million shares.
Navidea Biopharmaceuticals Inc (NAVB) on September 16, 2016 announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion for a new Lymphoseek® 50 microgram kit for radiopharmaceutical preparation. Lymphoseek is a medicinal product for diagnostic use only and is indicated in the EU for imaging and intraoperative detection of sentinel lymph nodes draining a primary tumor in adult patients with breast cancer, melanoma, or localized squamous cell carcinoma of the oral cavity.1 This new Lymphoseek “dose packaging” enables a single injection per patient and is appropriate for the radiopharmaceutical distribution model in Europe.
“This is an important milestone achieved by both Navidea and our partner SpePharm AG and was achieved through great collaboration by both companies,” said William J. Regan, Navidea Senior Vice President and Director Navidea UK, Ltd. “We are excited that Lymphoseek, with proven clinical benefits and performance characteristics which may improve the clinical outcomes of oncology patients, will shortly be available throughout Europe. The impact of this new dose packaging will also be important to Lymphoseek distribution as we register in markets throughout the rest of the world.”
Shares of Abbott Laboratories (NYSE:ABT) ended Monday session in green amid volatile trading. The shares closed up +0.34 points or 0.82% at $41.92 with 5.46 million shares getting traded. Post opening the session at $41.62, the shares hit an intraday low of $41.26 and an intraday high of $42.01 and the price vacillated in this range throughout the day. The company has a market cap of $61.47 billion and the numbers of outstanding shares have been calculated to be 1.47 billion shares.
Abbott Laboratories (ABT) will announce its third-quarter 2016 financial results on Wednesday, Oct. 19, 2016, before the market opens.
The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern), and will be accessible through Abbott’s Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available after 11 a.m. Central time.